Related Experiment Videos
[Chlamydia pneumoniae infection and cardiac ischemic syndromes]
A Varveri1, L Sgorbini, S Romano
1Dipartimento di Scienze Cardiovascolari e Respiratorie, Università degli Studi La Sapienza, Roma.
Insights
Chlamydia pneumoniae antibodies were found more frequently in patients with acute myocardial infarction and chronic ischemic heart disease compared to controls. This suggests a potential link between Chlamydia pneumoniae infection and the development of coronary artery disease.
Area of Science:
- Cardiology
- Infectious Diseases
- Immunology
Background:
- Coronary artery disease (CAD) is a leading cause of mortality worldwide.
- The role of infectious agents in the pathogenesis of atherosclerosis is increasingly recognized.
- Chlamydia pneumoniae is a potential etiological agent implicated in cardiovascular diseases.
Purpose of the Study:
- To investigate the seroprevalence of Chlamydia pneumoniae antibodies in patients with atherosclerotic coronary artery disease.
- To compare antibody titers between patients with acute myocardial infarction (AMI), chronic ischemic heart disease (CAD), and a healthy control group.
Main Methods:
- Microimmunofluorescence method used to detect IgM, IgG, and IgA anti-Chlamydia pneumoniae antibodies.
- Serum samples collected from 114 patients (72 AMI, 42 CAD) and 50 controls.
- Defined positive antibody titers for acute and chronic infections.
Main Results:
- Elevated IgG antibody titers were significantly higher in AMI (58.3%) and CAD (42.8%) groups compared to controls (38%).
- IgA positivity was also higher in CAD patients (33.3%) versus controls (22%).
- Evidence of acute or chronic Chlamydia pneumoniae infection was observed in AMI and CAD patients but not in controls.
Conclusions:
- Chlamydia pneumoniae infection is more prevalent in patients with atherosclerotic coronary artery disease.
- The findings suggest a potential association between Chlamydia pneumoniae and atherosclerosis.
- Further research is warranted to elucidate the mechanisms linking this infection to cardiovascular disease, possibly involving endothelial damage or inflammatory processes.
Abstract:
The aim of this study was to assess the presence of Chlamydia pneumoniae antibodies in patients with angiographically verified atherosclerotic coronary artery disease. A total of 114 consecutive patients were investigated between April 1995 and June 1996. Patients were divided into two groups: 72 patients with acute myocardial infarction (AMI; 53 men, 19 women, mean age 62.27 +/- 10.1 years), and 42 patients with chronic ischemic heart disease (CAD; 37 men, 5 women, mean age 62.75 +/- 9.2 years). A control group of 50 normal subjects matched for age (mean 62 +/- 9 years), sex, social status and geographical area was used. Identification of Chlamydia pneumoniae was carried out with the microimmunofluorescence method, on two serum samples taken from patients on admission and after 15 days. The IgM, IgG and IgA anti-Chlamydia pneumoniae titers were assessed, values > or = 1:16, > or = 1:32 and > or = 1:8 being respectively considered positive. Acute (IgM > or = 16 or four fold rise of IgG titer) and chronic (IgG > or = 128 e IgA > or = 32 or only elevated IgA titer) infections were analyzed. IgM antibodies were not found in AMI, CAD and control groups. IgG positivity (IgG > or = 32) was found in 38% of the control group, in 58.3% of the AMI group (p < 0.05) and 42.8% of the CAD group (p < 0.01). IgA positivity > or = 8) was found in 22% of the control group, in 31.9% of the AMI group (NS) and in 33.3% of the CAD group (p < or = 0.05). Acute infection was observed in 5.5% of AMI patients and in 12% of CAD patients (NS), whereas no subject of the control group showed these values. Chronic infection was observed in 9.7% of AMI patients and in 16.6% of CAD patients (NS) whereas nobody of the control group showed these values. In conclusion, our results suggest that Chlamydia pneumoniae infection is present only in the AMI and CAD groups. It is possible to suppose that this infection may be linked to atherosclerosis through an endothelial damage or a systemic endogenous procoagulant and inflammatory activity.